Citi keeps AUD 140.00 target for Cochlear stock

Published on 10/20/2026 at 21:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi keeps its AUD 140.00 target on October 20, 2026. Cochlear stock costs EUR 86.51 on October 20, 2026 at 9:20 p.m. CEST.

Citi target and earnings

Citi maintained a Hold rating and an AUD 140.00 target on October 20, 2026.
Cochlear reported AUD 2.35 billion in FY2026 revenue and AUD 147.30 million in net income.
Cochlear stock cost EUR 86.51 at Lang & Schwarz on October 20, 2026 at 9:20 p.m. CEST.

Cochlear, AU000000COH5, Illustration mit AI erstellt.

Cochlear Limited (AU000000COH5) was trading at EUR 86.51 at Lang & Schwarz on October 20, 2026 at 9:20 p.m. CEST. Citi maintained a Hold rating and an AUD 140.00 price target for the company on October 20, 2026, according to TipRanks.

Citi leaves the target unchanged

The Citi assessment keeps the Australian hearing-implant maker's target at AUD 140.00 while retaining a Hold view. The target is stated in Australian dollars and is separate from the euro quotation used for German investors.

Cochlear's latest annual reporting period ended June 30, 2026. The company recorded AUD 2.35 billion in revenue and AUD 147.30 million in net income, while its net profit margin was 6.3 percent, down from 17.0 percent in fiscal year 2025, according to Simply Wall St.

Revenue holds while profit contracts

The earnings profile puts the analyst target in a cautious setting. Revenue remained at AUD 2.35 billion in fiscal year 2026, but net income was AUD 147.30 million and the margin was 10.7 percentage points lower than in fiscal year 2025. That contrast leaves profitability as the central valuation question.

Cochlear is listed on the Australian Securities Exchange under ticker COH, according to Sanor. Its business centers on implantable auditory solutions for children and adults, including cochlear implants, sound processors, bone-conduction devices and accessories.

Price and valuation frame

On the Australian exchange, Cochlear last traded at AUD 139.40 on October 20, 2026 at 4:10 p.m. AEDT. The current market capitalization was AUD 9.1 billion, the price-to-earnings ratio was 62.23 and the dividend yield was 2.00 percent. The 52-week range was AUD 88.74 to AUD 296.50.

For comparison, CSL traded at AUD 196.30 with a price-to-earnings ratio of minus 25.92 and a market capitalization of AUD 94.2 billion on October 20, 2026. ResMed traded at AUD 34.20 with a price-to-earnings ratio of 23.57 and a market capitalization of AUD 48.1 billion on the same date.

What the target means for investors

Citi's AUD 140.00 target sits close to Cochlear's AUD 139.40 Australian quotation, while the lower fiscal-year margin shows why the rating remains cautious. The euro quotation gives German investors a separate trading reference after the Xetra session.